Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 3/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CCR6 | P51684 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 7/20 | 0.34 |
| ▸ | REN | P00797 | 3/20 | 0.34 |
| ▸ | CTSD | P07339 | 3/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2797770 | 0.82 | ACACB (0.51) | ACACBDRD1MEN1KMT2AALDH1A1 | |
| SCHEMBL3846192 | 0.78 | GRM5 (0.39) | ACACBMEN1KMT2AALDH1A1 | |
| SCHEMBL9060995 | 0.77 | ACACB (0.49) | ACACBDRD1MEN1KMT2AALDH1A1 | |
| SCHEMBL1306384 | 0.77 | GABRA1 (0.38) | MEN1KMT2AALDH1A1LMNAPKM | |
| SCHEMBL673162 | 0.76 | APP (0.55) | ACACBMEN1KMT2AALDH1A1RAB9A | |
| SCHEMBL31014818 | 0.76 | GRM5 (0.39) | — | |
| SCHEMBL4313333 | 0.75 | BACE1 (0.38) | BACE1RENCTSDBACE2 | |
| SCHEMBL1306505 | 0.75 | APP (0.41) | MEN1KMT2AALDH1A1LMNAPKM | |
| SCHEMBL28735922 | 0.75 | APP (0.35) | — | |
| SCHEMBL714294 | 0.75 | APP (0.59) | ACACBMEN1KMT2AALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168106-A1 | Amino-5-(5-membered)heteroarylimidazolone Compounds And The Use Thereof For Beta-secretase Modulation | WYETH LLC (US) | 2010-07-01 | — | — | US | disclosed |
| US-7705030-B2 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation | WYETH LLC (US) | 2010-04-27 | — | — | US | disclosed |
| US-20090042908-A1 | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR BETA-SECRETASE MODULATION | WYETH (US) | 2009-02-12 | — | — | US | disclosed |
| US-20080306091-A1 | AMINO-5-(5-MEMBERED)HETERO-ARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR beta-SECRETASE MODULATION | WYETH (US) | 2008-12-11 | — | — | US | disclosed |
| US-7452885-B2 | Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation | WYETH (US) | 2008-11-18 | — | — | US | disclosed |
| US-7417047-B2 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for β-secretase modulation | WYETH (US) | 2008-08-26 | — | — | US | disclosed |
| EP-1896454-A1 | AMlNO-5-(5-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR -SECRETASE MODULATION | Wyeth a Corporation of the State of Delaware (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1896448-A1 | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION | Wyeth (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007005366-A1 | AMlNO-5-(5-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR β-SECRETASE MODULATION | WYETH (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007005404-A1 | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION | WYETH (US) | 2007-01-11 | — | — | WO | disclosed |
| US-20070004730-A1 | Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
| US-20070004786-A1 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation | WYETH (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004730-A1 | Amino-5-(6-membered)heteroarylimidazolone compounds and the use thereof for beta-secretase modulation | BACE1, BACE2, APP | ACACB 477/4885DRD1 4801/4885MEN1 3951/4885 |
| US-20090042908-A1 | AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR BETA-SECRETASE MODULATION | BACE1, BACE2, APP | ACACB 477/4885DRD1 4801/4885MEN1 3951/4885 |
| US-20070004786-A1 | Amino-5-(5-membered)hetero-arylimidazolone compounds and the use thereof for beta-secretase modulation | BACE1, BACE2, APP | ACACB 567/4885DRD1 4736/4885MEN1 4193/4885 |
| US-20080306091-A1 | AMINO-5-(5-MEMBERED)HETERO-ARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR beta-SECRETASE MODULATION | BACE1, BACE2, APP | ACACB 567/4885DRD1 4736/4885MEN1 4193/4885 |
| US-20100168106-A1 | Amino-5-(5-membered)heteroarylimidazolone Compounds And The Use Thereof For Beta-secretase Modulation | BACE1, BACE2, APP | ACACB 490/4885DRD1 4794/4885MEN1 3922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.